{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'Similarly, olaparib monotherapy has also been shown to be well tolerated in patients with', 'advanced solid tumors, including mCRPC patients.', '2.', 'STUDY OBJECTIVES', '2.1', 'Primary objective', 'Determine the PSA50 response rate (i.e., percent of patients with a PSA decline of at least 50%', 'below baseline) following 12-weeks of treatment with bipolar androgen therapy (BAT) plus', 'olaparib in men with asymptomatic metastatic castration-resistant prostate cancer (mCRPC)', 'who have progressed on abiraterone and/or enzalutamide.', '2.2', 'Secondary objectives', '1. Determine the percent of mCRPC patients achieving a radiographic response per', 'RECIST 1.1 criteria following treatment with BAT plus olaparib.', '2. Determine the radiographic progression free survival (PFS) in mCRPC patients treated', 'with BAT plus olaparib using RECIST 1.1 criteria for soft tissue metastases and', 'Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases [95, 96].', '3. Determine the PSA PFS rate according to PCWG3 criteria in mCRPC patients treated', 'with BAT plus olaparib [95].', '4. Determine the PFS (i.e. whichever occurs first: clinical, radiographic or PSA', 'progression) in mCRPC patients treated with BAT plus olaparib.', '5. Determine the overall survival in mCRPC patients treated with BAT plus olaparib.', '6. Track changes in quality of life (QoL) as determined using the FACT-P and', 'International Index of Erectile Function (IIEF) surveys.', '7. Assess the incidence and severity of adverse events according to the National Cancer', 'Institute - Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.', '2.3', 'Exploratory objectives', 'Correlative work will be conducted in order to better understand the biology underlying', 'response and resistance to BAT plus olaparib in men with mCRPC. Serial blood samples and', 'metastatic tissue will be obtained at baseline and upon progression. Examples of studies to be', 'conducted may include, but are not limited to:', '1. Evaluate for differences in response and PFS in patients with/without mutations in', 'genes involved in homologous recombination.', '2. Determine intratumoral androgen levels using liquid chromatography-mass', 'spectrometry (LC/MS)', '3. Assess for evidence of dsDNA breaks using y-H2AX immunostaining on circulating', 'tumor cells (CTCs) and metastatic tissue', '4. Assess androgen receptor (AR) and AR splice variant (AR-V) transcript expression', 'levels using qRT-PCR on CTCs', '5. Assess androgen receptor (AR) and AR splice variant (AR-V) protein expression levels', 'using immunostaining on circulating tumor cells (CTCs) and metastatic tissue', '31(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '6. Sequence tumor DNA (cell-free circulating tumor DNA [ctDNA] and/or metastatic', 'tissue)', '7. Conduct transcript profiling studies on CTCs (multiplexed qRT-PCR) and metastatic', 'tissue (RNA-seq)', '3.', 'PATIENT SELECTION CRITERIA', 'Number of patients: 30 response evaluable mCRPC patients that have progressed on', 'abiraterone and/or enzalutamide will be recruited from the Seattle Cancer Care', 'Alliance/University of Washington Medical Center (SCCA/UWMC) genitourinary oncology', 'clinic.', 'Number of centers: One.', '3.1', 'Inclusion criteria', 'For inclusion in the study patients should fulfill the following criteria:', '1. Must be willing to provide informed consent prior to any study specific procedures', '2. Age > 18 years.', '3. Documented histologically confirmed adenocarcinoma of the prostate.', '4. Patient must have evidence of castration resistant prostate cancer as evidenced by PSA', 'progression (per Prostate Cancer Working Group 3 [PCWG3] criteria) and a castrate', 'serum testosterone level (i.e., 50 mg/dL) [95].', '5.', 'PSA must be at least 1 ng/ml and rising on two successive measurements at least two', 'weeks apart.', '6. Patients must have progressed on abiraterone and/or enzalutamide. There must be at least', 'a 3-week washout period after stopping the most recent approved therapy for mCRPC', '(i.e., abiraterone, enzalutamide, Ra-223, sipuleucel-t). If applicable, patients should be', 'weaned off steroids at least 1 week prior to starting treatment.', '7. No prior chemotherapy for the treatment of mCRPC. Patients may have received docetaxel', 'for the treatment of hormone-sensitive prostate cancer.', '8.', 'Prior treatment with non-chemotherapy investigational agents is permitted. There must be', 'at least a 3-week washout period after stopping any investigational cancer agent.', '9. Patients must have normal organ and bone marrow function measured within 28 days prior', 'to administration of study treatment as defined below:', '-', 'Hemoglobin > 10.0 g/dL with no blood transfusion in the past 28 days', '32(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}